Regeneron Pharmaceuticals REGN TD Cowen Ups Price Target Ahead of Fiscal Q1 Results Supported by FDA Gene Therapy Approval KLX Energy KLXE Stock vs Peers Trend Strengthens 20260427 Lucid Group LCID Assessing the RiskReward Opportunity at Its MultiYear Price Low What market indicators CartesianIII CGCTU Overhead Buying 20260427 KYMR Kymera Therapeutics posts wider than expected Q4 2025 loss sending shares down 259 percent today